Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma
22 Jan, 2021 | 07:59h | UTCOnset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW Research—#Benralizumab significantly reduced exacerbation risk by 49% vs placebo (RR estimate 0·51, 95% CI 0·39–0·65; p≤0·0001) over the 24-week treatment period in patients with severe eosinophilic #asthma
The ANDHI study from Tim Harrison & co https://t.co/bQwikpQZvc pic.twitter.com/sS9ab0Mo1R
— The Lancet Respiratory Medicine (@LancetRespirMed) January 4, 2021